|
|
Volumn 6, Issue 3, 2002, Pages
|
|
Rituximab as third-line treatment for refractory or recurrent stage III or IV follicular non-Hodgkin's lymphoma: A systematic review and economic evaluation
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALKYLATING AGENT;
ALPHA INTERFERON;
ANTHRACYCLINE DERIVATIVE;
ANTINEOPLASTIC AGENT;
CHLORAMBUCIL;
CLADRIBINE;
CYCLOPHOSPHAMIDE;
DOXORUBICIN;
FLUDARABINE;
IMMUNOMODULATING AGENT;
PREDNISOLONE;
RITUXIMAB;
STEROID;
VINCRISTINE;
MONOCLONAL ANTIBODY;
BLOOD TOXICITY;
BONE MARROW SUPPRESSION;
CANCER ADJUVANT THERAPY;
CANCER RECURRENCE;
CANCER REGRESSION;
CANCER RESEARCH;
CANCER STAGING;
CANCER SURVIVAL;
CLINICAL PROTOCOL;
CLINICAL TRIAL;
COST EFFECTIVENESS ANALYSIS;
DRUG COST;
DRUG EFFICACY;
DRUG RESPONSE;
ECONOMIC ASPECT;
FOLLICULAR LYMPHOMA;
HUMAN;
IMMUNE DEFICIENCY;
NAUSEA AND VOMITING;
NEUROTOXICITY;
NONHODGKIN LYMPHOMA;
PATIENT SATISFACTION;
QUALITY OF LIFE;
REVIEW;
STEM CELL TRANSPLANTATION;
BIOMEDICAL TECHNOLOGY ASSESSMENT;
CONTROLLED CLINICAL TRIAL;
COST BENEFIT ANALYSIS;
DRUG RESISTANCE;
ECONOMICS;
PATHOLOGY;
PATIENT COMPLIANCE;
RANDOMIZED CONTROLLED TRIAL;
RESEARCH;
SURVIVAL;
TREATMENT OUTCOME;
TUMOR RECURRENCE;
UNITED KINGDOM;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
COST-BENEFIT ANALYSIS;
DRUG COSTS;
DRUG RESISTANCE, NEOPLASM;
GREAT BRITAIN;
HUMANS;
LYMPHOMA, FOLLICULAR;
NEOPLASM RECURRENCE, LOCAL;
NEOPLASM STAGING;
PATIENT COMPLIANCE;
RANDOMIZED CONTROLLED TRIALS;
RESEARCH;
SURVIVAL ANALYSIS;
TECHNOLOGY ASSESSMENT, BIOMEDICAL;
TREATMENT OUTCOME;
|
|
EID: 0036097550
PISSN: 13665278
EISSN: None
Source Type: Journal
DOI: 10.3310/hta6030 Document Type: Review |
|
Times cited : (22)
|
|
References (52)
|
